Liothyronine use in a 17 year observational population-based study - the tears study

Clinical Endocrinology

Volumn 85, Issue 6, 2016, Pages 918-925

  Leese, Graham P ^a   Soto Pedre, Enrique ^a   Donnelly, Louise A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LIOTHYRONINE; NEUROLEPTIC AGENT; THYROXINE;

ADULT; ADVERSE OUTCOME; ARTICLE; ATRIAL FIBRILLATION; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; FRACTURE; HORMONE SUBSTITUTION; HOSPITAL ADMISSION; HUMAN; HYPOTHYROIDISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY RATE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCOTLAND; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPARATIVE STUDY; MIDDLE AGED;

ANTIPSYCHOTIC AGENTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROXINE; TRIIODOTHYRONINE;

EID: 84961683917     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13052     Document Type: Article

References (34)

1. Garber, J.R., Cobin, R.H., Gharib, H. et al. (2012) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocrine Practice, 18, 988–1028.
2. Wiersinga, W., Duntas, L.H., Fadeyev, V.V. et al. (2012) 2012 ETA Guidelines: the Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. European Thyroid Journal, 1, 55–71.
3. Saravanan, P., Simmons, D.J., Greenwood, R. et al. (2005) Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism, 90, 805–812.
4. Bunevicius, R., Kazanavicius, G., Zalinkevicius, R. et al. (1999) Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. The New England Journal of Medicine, 340, 424–429.
5. Nygaard, B., Jensen, E.W., Kvetny, J. et al. (2009) Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. European Journal of Endocrinology, 161, 895–902.
6. Valizadeh, M., Seyyed-Majidi, M.R., Hajibeigloo, H. et al. (2009) Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocrine Research, 34, 80–89.
7. Rodriguez, T., Lavis, V.R., Meininger, J.C. et al. (2005) Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone. Endocrine Practice, 11, 223–233.
8. Walsh, J.P., Shiels, L., Lim, E.M. et al. (2003) Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. The Journal of Clinical Endocrinology and Metabolism, 88, 4543–4550.
9. Appelhof, B.C., Fliers, E., Wekking, E.M. et al. (2005) Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. The Journal of Clinical Endocrinology and Metabolism, 90, 2666–2674.
10. Sawka, A.M., Gerstein, H.C., Marriott, M.J. et al. (2003) Does a combination regimen of thyroxine (T4) and 3,5,3′-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double blind, randomized, controlled trial. The Journal of Clinical Endocrinology and Metabolism, 88, 4551–4555.
11. Bunevicius, R., Jakubonien, N., Jurkevicius, R. et al. (2002) Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine, 18, 129–133.
12. Clyde P.W, Harari A.E & Getka, E.J et al. (2003) Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 290, 2952–2958.
13. Escobar-Morreale, H.F., Botella-Carretero, J.I., Gomez-Bueno, M. et al. (2005) Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Annals of Internal Medicine, 142, 412–424.
14. Siegmund W, Spieker K & Weike., A.I et al. (2004) Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14: 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clinical Endocrinology 60, 750–757.
15. Fadeyev, V.V., Morgunova, T.B., Melnichenko, G.A. et al. (2010) Combined therapy with L-thyroxine and L-triiodothyronine compared to L-thyroxine alone in the treatment of primary hypothyroidism. Hormones, 9(3), 245–252.
16. Panicker, V., Saravanan, P., Vaidya, B. et al. (2009) Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. The Journal of Clinical Endocrinology and Metabolism, 94, 1623–1629.
17. Appelhof, B.C., Peeters, R.P., Wiersinga, W.M. et al. (2005) Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. The Journal of Clinical Endocrinology and Metabolism, 90, 6296–6299.
18. Grozinsky-Glasberg, S., Fraser, A. & Nahshoni, E. (2006) Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. The Journal of Clinical Endocrinology and Metabolism, 91, 2592–2599.
19. Escobar-Morreale, H.F., Botella-Carretero, J.I., Escobar del Rey, F. et al. (2005) REVIEW: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. The Journal of Clinical Endocrinology and Metabolism, 90, 4946–4954.
20. Joffe R.T, Brimacombe M & Levitt., A.J et al. (2007) Treatment of clinical hypothyroidism with thyroxine and triiodothyronine: a literature review and metaanalysis. Psychosomatics, 48, 379–384.
21. Ma, C., Xie, J., Huang, X. et al. (2009) Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nuclear Medicine Communications, 30, 586–593.
22. Vadiveloo, T., Donnan, P.T., Cochrane, L. et al. (2011) The Thyroid Epidemiology, Audit, and Research Study (TEARS): the Natural History of Endogenous Subclinical Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 96, 1344–1351.
23. ISD Scotland. SMR datasets; validation section (2015). Available from: http://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/SMR-Validation-Section/(accessed 23 November 2015).
24. ISD Scotland. Data quality assurance; assessments of SMR (2015). Available from: http://www.isdscotland.org/Products-and-Services/Data-Quality/Assessments/ (accessed 23 November 2015).
25. Maldonado, G. & Greenland, S. (1993) Simulation study of confounder-selection strategies. American Journal of Epidemiology, 138(11), 923–936.
26. Grambsch, P.M. & Therneau, T.M. (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 4(81), 515–526.
27. Collett, D. (1994) Modelling Survival Data in Medical Research, Chapman & Hall, London.
28. Mamtani, R., Haynes, K. & Finkelman, B.S. (2014) Distinguishing incident and prevalent diabetes in an electronic medical records database. Pharmacoepidemiology and Drug Safety, 4(23), 111–118.
29. Rothman, K.J. (1981) Induction and latent periods. American Journal of Epidemiology, 1(114), 253–259.
30. Cooper-Kazaz, R., Apter, J.T., Cohen, R. et al. (2007) Combined treatment with sertraline and liothyronine in major depression: a randomised double blind placebo controlled trial. Archives of General Psychiatry, 64, 679–688.
31. Hall, L.C., Salazar, E.P., Kane, S.R. et al. (2008) Effects of thyroid hormones on human breast cancer cell proliferation. Journal of Steroid Biochemistry and Molecular Biology, 8(109), 57–66.
32. De Sibio, M.T., de Oliveira, M., Moretto, F.C. et al. (2014) Triiodthyronine and breast cancer. World Journal of Clinical Oncology, 5, 503–508.
33. Tosovic, A., Bondeson, A.G., Bondeson, L. et al. (2014) T3 levels in relation to prognostic factors in breast cancer: a population-based prospective cohort study. BMC Cancer, 14, 536.
34. Tosovic, A., Bondeson, A.G., Bondeson, L. et al. (2013) Triiodothyronine levels in relation to mortality from breast cancer and all causes: a population-based prospective cohort study. European Journal of Endocrinology, 168, 483–490.